Literature DB >> 25556685

Painful peripheral neuropathy and sodium channel mutations.

Janneke G J Hoeijmakers1, Catharina G Faber2, Ingemar S J Merkies3, Stephen G Waxman4.   

Abstract

Peripheral neuropathy can lead to neuropathic pain in a subset of patients. Painful peripheral neuropathy is a debilitating disorder, reflected by a reduced quality of life. Therapeutic strategies are limited and often disappointing, as in most cases targeted treatment is not available. Elucidating pathogenetic factors for pain might provide a target for optimal treatment. Voltage-gated sodium channels NaV1.7-NaV1.9 are expressed in the small-diameter dorsal root ganglion neurons and their axons. By a targeted gene approach, missense gain-of-function mutations of NaV1.7-NaV1.9 have been demonstrated in painful peripheral neuropathy. Functional analyses have shown that these mutations produce a spectrum of pro-excitatory changes in channel biophysics, with the shared outcome at the cellular level of dorsal root ganglion hyperexcitability. Reduced neurite outgrowth may be another consequence of sodium channel mutations, and possible therapeutic strategies include blockade of sodium channels or block of reverse operation of the sodium-calcium exchanger. Increased understanding of the pathophysiology of painful peripheral neuropathy offers new targets that may provide a basis for more effective treatment.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Painful peripheral neuropathy; Small-fiber neuropathy; Voltage-gated sodium channels

Mesh:

Substances:

Year:  2014        PMID: 25556685     DOI: 10.1016/j.neulet.2014.12.056

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

1.  Naja atra venom peptide reduces pain by selectively blocking the voltage-gated sodium channel Nav1.8.

Authors:  Fan Zhang; Changxin Zhang; Xunxun Xu; Yunxiao Zhang; Xue Gong; Zuqin Yang; Heng Zhang; Dongfang Tang; Songping Liang; Zhonghua Liu
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

Review 2.  Sodium channels in astroglia and microglia.

Authors:  Laura W Pappalardo; Joel A Black; Stephen G Waxman
Journal:  Glia       Date:  2016-02-26       Impact factor: 7.452

3.  New Directions in the Treatment of Chronic Pain: National Pain Strategy Will Guide Prevention, Management, and Research.

Authors:  Susan L Worley
Journal:  P T       Date:  2016-02

4.  From Perception Threshold to Ion Channels-A Computational Study.

Authors:  Jenny Tigerholm; Aida Hejlskov Poulsen; Ole Kæseler Andersen; Carsten Dahl Mørch
Journal:  Biophys J       Date:  2019-06-14       Impact factor: 4.033

Review 5.  Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go?

Authors:  Zhi-Mei Li; Li-Xia Chen; Hua Li
Journal:  Curr Med Sci       Date:  2019-12-16

Review 6.  How to diagnose neuropathic pain? The contribution from clinical examination, pain questionnaires and diagnostic tests.

Authors:  S La Cesa; S Tamburin; V Tugnoli; G Sandrini; S Paolucci; M Lacerenza; P Marchettini; G Cruccu; A Truini
Journal:  Neurol Sci       Date:  2015-09-26       Impact factor: 3.307

Review 7.  TRPs et al.: a molecular toolkit for thermosensory adaptations.

Authors:  Lydia J Hoffstaetter; Sviatoslav N Bagriantsev; Elena O Gracheva
Journal:  Pflugers Arch       Date:  2018-02-27       Impact factor: 3.657

Review 8.  Physiology and Pathophysiology of Itch.

Authors:  Ferda Cevikbas; Ethan A Lerner
Journal:  Physiol Rev       Date:  2019-12-23       Impact factor: 37.312

9.  Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres.

Authors:  Roberta Carbonara; Alessia Carocci; Julien Roussel; Giuseppe Crescenzo; Canio Buonavoglia; Carlo Franchini; Giovanni Lentini; Diana Conte Camerino; Jean-François Desaphy
Journal:  Front Pharmacol       Date:  2015-07-24       Impact factor: 5.810

Review 10.  Voltage-gated sodium channels and cancer: is excitability their primary role?

Authors:  Sébastien Roger; Ludovic Gillet; Jean-Yves Le Guennec; Pierre Besson
Journal:  Front Pharmacol       Date:  2015-07-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.